Zai Lab Ltd (ZLAB)

$86.69 0.00 (0.00%)

16:50 EDT ZLAB Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 4.33B

PE Ratio -37.37

EPS -2.32

Volume (Avg. Vol.)

Day's Range 86.69 - 86.69

52-Week Range 29.43 - 95.51

Dividend & Yield N/A (N/A)

ZLAB Stock Predictions, Articles, and Zai Lab Ltd News

From InvestorPlace
From the Web

This Stock Points to the Massive China Biotech Trend

By Matt McCall, Editor, MoneyWire Apr 23, 2020

There is ridiculously big upside potential for Chinese biotech stocks in the next decade. The spread of the pandemic has only strengthened the case.

7 Exciting Biotech Stocks to Buy Now

By Louis Navellier, Editor, Growth Investor Dec 2, 2019

Many of these biotech companies are beating the Nasdaq Biotech Index. With cutting-edge therapies, these are great names to buy.

The Daily Biotech Pulse: Patent Award For Theratechnologies, Enzo Biochem's Q4, Codiak Debuts

From Benzinga Oct 14, 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 13) 10X Genomics Inc (NASDAQ:...

The Daily Biotech Pulse: J&J Pauses Coronavirus Vaccine Studies, Voyager's Huntington's Disease Study Placed On Hold, Altimmune Vaccine Data

From Benzinga Oct 13, 2020

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12) 10X Genomics Inc (NASDAQ:...

Stocks That Hit 52-Week Highs On Monday

From Benzinga Oct 12, 2020

This morning 239 companies reached new 52-week highs. Things to Consider: Alibaba Group Holding (NYSE: BABA) was the largest firm on a market cap basis to set a new 52-...

Stocks That Hit 52-Week Highs On Friday

From Benzinga Oct 9, 2020

This morning 221 companies reached new 52-week highs. Noteworthy Points: The largest company on a market cap basis to set a new 52-week high was Procter & Gamble (NYSE...

Week In Review: $1.5 Billion Total In Week's China Deals

From Talk Markets Oct 10, 2020

Everest Medicines of Shanghai completed a $451 million IPO in Hong Kong to develop its portfolio of eight assets in-licensed for China development. The company's stock climbed 32% in its first trading session.

The Daily Biotech Pulse: FDA Panel Review For Alkermes, Axovant Gets Rare Pediatric Disease Designation, 2 IPOs

From Benzinga Oct 9, 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 8) 10X Genomics Inc (NASDAQ:...

Navellier Ratings

Powered by Portfolio Grader

Total Grade

A

Strong Buy